Clinical Trials Browser

Phase 4 × Everolimus × Clear all

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT05252585 2026-02-03

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Phase 4 Active not recruiting

4 enrolled

Tuberous Sclerosis, Angiomyolipoma

NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4 Completed

61 enrolled 9 charts

EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT03525834 2021-09-09

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Phase 4 Completed

40 enrolled 10 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT01743560 2019-07-18

4EVERUK

Phase 4 Completed

52 enrolled 16 charts

Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Skin Diseases

NCT01206764 2019-06-24

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Phase 4 Completed

143 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell

NCT01595009 2018-11-29

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Phase 4 Completed

246 enrolled 16 charts

EndocrineNET

Neuroendocrine Tumors

NCT02338570 2018-02-05

ORCHIDEE

Phase 4 Terminated

31 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01266837 2017-11-14

MARC-2

Phase 4 Completed

64 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02248571 2017-11-13

IMPROVE

Phase 4 Completed

85 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01514448 2017-07-19

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Phase 4 Completed

29 enrolled 9 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02056587 2014-02-06

Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment

Phase 4 Completed

37 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00903188 2009-05-18

CISTCERT

Phase 4 Unknown

152 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

4EVERUK

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

ORCHIDEE

MARC-2

IMPROVE

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment

CISTCERT